glp-1 obesity drug news today september 15 2025 The first of three of our Appetite for Answers series! Understanding GLP-1s Beyond the Headlines medications are currently a major topic of discussion, and unfortunately, misinformation is spreading—not only among the Swiss Re says GLP-1 drugs

Unfortunately, utilization of Saxenda has significantly declined in recent years and now represents less than 1% of the anti-obesity medication market

View Article This article is provided for educational and informational purposes only

That prompted Katz to post a question on a national neuro-ophthalmology listserv to see if his colleagues were seeing similar things in their patients

Although you will not be able to take retatrutide for weight loss until it has received approval from the FDA, you can use other medications now, and you can receive an evaluation for a prescription through Klinic

Subsequently, Novo Nordisk developed an oral formulation Rybelsus, the first launched oral GLP-1RA, by combining semaglutide with intestinal permeation enhancer SNAC [7][8]

Effect of GLP-1 receptor agonists on lean body mass: a network meta-analysis